15 May 2024 - Health technology assessment guidance often recommends a 3% real annual discount rate, the appropriateness of which ...
1 May 2024 - As of today, we will adopt Canada’s Drug Agency (CDA-AMC) as our new operating name. ...
1 May 2024 - The outcomes from the February 2024 PTAC meeting are now available. ...
1 May 2024 - Submission included data from the Phase 3 QUASAR program in ulcerative colitis and the Phase 3 GALAXI ...
30 April 2024 - Neurocrine Biosciences today announced the US FDA has approved Ingrezza Sprinkle (valbenazine) capsules, a new oral ...
29 April 2024 - Potential approval early Q4, 2024. ...
29 April 2024 - Announces immediate availability of Libervant 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg for ...
29 April 2024 - Bavarian Nordic today announced that it has initiated the rolling submission process with the US FDA ...
1 May 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
1 May 2024 - NICE has published updated evidence-based recommendations on the pembrolizumab (Keytruda) for the treatment of patients with ...
30 April 2024 - Company anticipates 10 month review for potential approval in Q1, 2025. ...
30 April 2024 - A new cancer treatment recently approved in Canada promises to cut treatment time down to just ...
29 April 2024 - A US judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson ...
1 May 2024 - The May 2024 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
1 May 2024 - The May 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
29 April 2024 - FDA PDUFA action expected in Q4, 2024. ...